New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes

Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge

(2020) Nina Dieu Nhien Tran Nguyen et al.   npj Vaccines

Nanoparticle Size Influences Antigen Retention and Presentation in Lymph Node Follicles for Humoral Immunity

(2019) Yi-Nan Zhang et al.   NANO LETTERS

Targeting the Latent Reservoir for HIV-1

(2018) Srona Sengupta et al.   IMMUNITY

Vaccination with the conserved caveolin-1 binding motif in HIV-1 glycoprotein gp41 delays the onset of viral infection and provides partial protection in SHIV-challenged cynomolgus macaques

(2018) Ara G. Hovanessian et al.   JOURNAL OF VIROLOGY

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis

(2018) Maxence Duchemin et al.   Frontiers in Immunology

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica

(2018) Mayuresh M. Abhyankar et al.   npj Vaccines

Lymph node targeting strategies to improve vaccination efficacy

(2017) Hao Jiang et al.   JOURNAL OF CONTROLLED RELEASE

Critical Role for Skin-Derived Migratory DCs and Langerhans Cells in T FH and GC Responses after Intradermal Immunization

(2017) Clément Levin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir

(2017) Michael T. Hensel et al.   JOURNAL OF VIROLOGY

Economic impact of thermostable vaccines

(2017) Bruce Y. Lee et al.   VACCINE

The origins of the vaccine cold chain and a glimpse of the future

(2017) John Lloyd et al.   VACCINE

Antibody-mediated immune exclusion of HIV

(2017) Ruth M. Ruprecht et al.   Current Opinion in HIV and AIDS

Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design

(2017) Adriana Irimia et al.   PLoS Pathogens

Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target

(2017) Luis M. Molinos-Albert et al.   Frontiers in Immunology

Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice

(2017) Thomas Ebensen et al.   Frontiers in Immunology

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

(2017) Susan P. Buchbinder et al.   PLoS One

Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial

(2017) G. Haidari et al.   Scientific Reports

Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses

(2016) John D. Clements et al.   Clinical and Vaccine Immunology

Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10

(2016) Adriana Irimia et al.   IMMUNITY

Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine

(2016) Miyuki Tozuka et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects

(2016) Yunda Huang et al.   JOURNAL OF IMMUNOLOGY

Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16

(2016) B M Gunn et al.   Mucosal Immunology

Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying

(2016) Phillip M. Lovalenti et al.   PHARMACEUTICAL RESEARCH

A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly

(2016) Yotam Levin et al.   VACCINE

Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques

(2015) Mark Spengler et al.   ANALYST

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

(2015) D. H. Barouch et al.   SCIENCE

Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries

(2015) Christopher L. Karp et al.   VACCINE

Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge

(2015) Anton M. Sholukh et al.   VACCINE

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein

(2015) Russell Vassell et al.   PLoS One

Emerging Technologies to Increase Ligand Binding Assay Sensitivity

(2014) Saloumeh K. Fischer et al.   AAPS Journal

Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope

(2014) Soraya Serrano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Influenza virosomes as vaccine adjuvant and carrier system

(2013) Christian Moser et al.   Expert Review of Vaccines

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

(2013) Geert Leroux-Roels et al.   PLoS One

Innate Immune Function by Toll-like Receptors: Distinct Responses in Newborns and the Elderly

(2012) Tobias R. Kollmann et al.   IMMUNITY

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

(2012) Jinghe Huang et al.   NATURE

Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form

(2012) Aditya Pattani et al.   VACCINE

Immune response to vaccine adjuvants during the first year of life

(2012) Ofer Levy et al.   VACCINE

Influenza virosomes as a vaccine adjuvant and carrier system

(2011) Christian Moser et al.   Expert Review of Vaccines

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

(2011) Morgane Bomsel et al.   IMMUNITY

Caspase-1-induced pyroptotic cell death

(2011) Edward A. Miao et al.   IMMUNOLOGICAL REVIEWS

Evaluation of the Sublingual Route for Administration of Influenza H5N1 Virosomes in Combination with the Bacterial Second Messenger c-di-GMP

(2011) Gabriel Kristian Pedersen et al.   PLoS One

Vaccine stabilization: Research, commercialization, and potential impact

(2011) Debra Kristensen et al.   VACCINE

Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction

(2011) Dmitri Smirnov et al.   VACCINE

New insights in mucosal vaccine development

(2011) Vincent Pavot et al.   VACCINE

Protocols for Hematopoietic Stem Cell Expansion from Umbilical Cord Blood

(2010) Sonja Koestenbauer et al.   CELL TRANSPLANTATION

A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation

(2010) V. Saluja et al.   JOURNAL OF CONTROLLED RELEASE

GP41-Specific Antibody Blocks Cell-Free HIV Type 1 Transcytosis through Human Rectal Mucosa and Model Colonic Epithelium

(2010) R. Shen et al.   JOURNAL OF IMMUNOLOGY

Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design

(2010) Jiri Mestecky et al.   JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Multiple Vaccine-Elicited Nonneutralizing Antienvelope Antibody Activities Contribute to Protective Efficacy by Reducing both Acute and Chronic Viremia following Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques

(2010) P. Xiao et al.   JOURNAL OF VIROLOGY

Targeting early infection to prevent HIV-1 mucosal transmission

(2010) Ashley T. Haase   NATURE

Opportunities and challenges of developing thermostable vaccines

(2009) Dexiang Chen et al.   Expert Review of Vaccines

What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens?

(2009) I. M. Belyakov et al.   JOURNAL OF IMMUNOLOGY

Virus-like Particle (VLP) Lymphatic Trafficking and Immune Response Generation After Immunization by Different Routes

(2009) Rafael Cubas et al.   JOURNAL OF IMMUNOTHERAPY

Virosomal Hepatitis A Vaccine: Comparing Intradermal and Subcutaneous With Intramuscular Administration

(2009) Gert Frösner et al.   JOURNAL OF TRAVEL MEDICINE

Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

(2009) A. J. Hessell et al.   JOURNAL OF VIROLOGY

Sensitivity by combination: immuno-PCR and related technologies

(2008) Michael Adler et al.   ANALYST

The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design

(2008) M. Montero et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study

(2007) Gilles Pialoux et al.   VACCINE